Axsome Therapeutics, Inc. Reports Strong Preliminary Net Product Revenue for 2023 and Anticipated Milestones for 2024
Axsome Therapeutics, Inc. a leading biopharmaceutical company, has announced its preliminary net product revenue for the fourth quarter and full year of 2023. The company has reported impressive results of $71 million and $204 million, respectively. These numbers do not include the $66 million in license revenue recognized in the first quarter of 2023.
The company’s two main products, Auvelity and Sunosi, have seen significant sales of $49 million and $22 million in the fourth quarter, and $130 million and $74 million for the full year, respectively. This is a testament to the strong commercial execution of Axsome’s products, with an increased field force effort.
In 2023, Axsome’s medicines reached approximately 100,000 unique patients, with over 236,000 prescriptions for Auvelity and 139,000 for Sunosi. The company is dedicated to providing innovative therapies for central nervous system disorders, and these numbers reflect its commitment to improving the lives of patients.
Looking ahead to 2024, Axsome has a busy year planned with multiple important clinical and regulatory milestones. These include topline results from Phase 3 trials in narcolepsy, Alzheimer’s disease agitation, and ADHD, as well as NDA resubmission and submission for migraine and fibromyalgia, respectively. The company also plans to initiate Phase 3 trials for major depressive disorder, binge eating disorder, and excessive sleepiness associated with shift work disorder.
Axsome’s development pipeline is impressive, with five late-stage product candidates for 10 serious conditions that affect more than 150 million people in the US alone. The company is dedicated to developing and delivering innovative treatments with novel mechanisms of action to address unmet medical needs in serious conditions that affect brain health.
Axsome Therapeutics, Inc. has reported strong preliminary net product revenue for 2023 and has an exciting year ahead with anticipated milestones for 2024.
